The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | ALEXANDER: bicistronic CD19 & CD22 CAR for DLBCL
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses the Phase 1 Alexander study (NCT03287817) of AUTO3, the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 with pembrolizumab in patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
